Frankreich

DGAP-News: Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy

Vendredi, mars 5, 2021 - 8:01pm

The study has a robust randomized, double-blind and placebo-controlled design to test whether ABX464 could prevent the development of severe Covid-19 disease in the participants.

Key Points: 
  • The study has a robust randomized, double-blind and placebo-controlled design to test whether ABX464 could prevent the development of severe Covid-19 disease in the participants.
  • The DSMB recommendation is based on a planned, interim analysis evaluating data of 305 high-risk Covid-19 patients who completed the study period.
  • Abivax, a clinical stage biotechnology company, is modulating the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer.
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

2CRSi SA: Information following the initiation of the receivership procedure of Blade SAS. Revised revenue target for 2020/21: €162-175 million.

Mercredi, mars 3, 2021 - 8:02pm

The company Blade SAS, the specialist of cloud PC for video game players, was placed in receivership proceedings by the Paris Commercial Court yesterday.

Key Points: 
  • The company Blade SAS, the specialist of cloud PC for video game players, was placed in receivership proceedings by the Paris Commercial Court yesterday.
  • In all contracts between the two companies, the servers provided remain the property of 2CRSi [1] until all lease payments or instalments are paid by Blade.
  • These servers that 2CRSi could take over are high-end graphics card (GPU) based compute servers and storage servers.
  • The financial debt corresponding to the financing of the contracts with Blade SAS amounts to 3.7 million as of today.

DGAP-News: Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology'

Mercredi, mars 3, 2021 - 6:02pm

The peer-reviewed article scientifically confirms the quality and robustness of the data generated in Abivax's randomized placebo-controlled, double-blind clinical study that consisted of an eight-week induction phase followed by an open-label long-term extension phase .

Key Points: 
  • The peer-reviewed article scientifically confirms the quality and robustness of the data generated in Abivax's randomized placebo-controlled, double-blind clinical study that consisted of an eight-week induction phase followed by an open-label long-term extension phase .
  • Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: "We are proud that "Gastroenterology" accepted the exciting results of our induction and long-term phase 2a maintenance study in moderate-to-severe ulcerative colitis patients with ABX464.
  • Therefore, we are preparing to move our lead molecule into a phase 3 clinical program in ulcerative colitis and to initiate a phase 2b/3 clinical trial in Crohn's disease.
  • ABX464 is currently being evaluated in a phase 2b UC clinical trial, a phase 2b/3 Covid-19 clinical trial and a phase 2a rheumatoid arthritis clinical trial.